Khiron Life Sciences Corp. (TSXV:KHRN) President Chris Naprawa was featured in an interview with the Midas Letter this week to discuss the company’s progress in Mexico. Naprawa is enthused by recently proposed legislative changes in Mexico that could include the legalization of recreational adult use, a major step for cannabis companies like Khiron. According to Naprawa, both sides of the Mexican government are in support of the proposed legislation and he hopes that the Mexican government will be able to deliver a full proposal by the end of 2019.

“There’s no opposition to legalization. What we’re trying to figure out now is which part of the government will manage that process, which part of the government will approve products and regulate them and inspect them. So we’ll find that out very, very shortly,” said Naprawa.

Naprawa also touched on Khiron’s joint venture with Dixie Brands (CSE:DIXIU), which will provide Dixie with access to US consumers while giving Khiron access to Dixie’s extensive portfolio of proprietary formulations. The partnership is a continuation of Khiron’s Latin American strategy, where the company continues to make inroads into regions like Columbia, Peru and Chile as they anticipate cannabis legalization in the area.

To watch the full Midas Letter interview with Khiron Life Sciences President Chris Naprawa click here.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation. 

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less